权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Whole Genome Sequencing for Schizophrenia and Bipolar Disorder in the GPC

GPC 中精神分裂症和双相情感障碍的全基因组测序

基本信息

批准号：
8929308
负责人：
MICHAEL L BOEHNKE
金额：
$ 57.06万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-09-19 至 2018-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8929308
关键词：
African Architecture Bipolar Disorder Brain Diseases California Chronic Code Collaborations Communities Complex Copy Number Polymorphism DNA Data Delusions Deposition Development Diagnosis Disease Dissection Elements Ensure Etiology European Family First Degree Relative Frequencies Functional disorder Future Genes Genetic Genetic study Genome Genomic DNA Genomics Genotype Goals Hallucinations Haplotypes Health Heritability High-Throughput DNA Sequencing Human Genetics Impaired cognition Individual Institutes Knowledge Latino Leadership Libraries Life Manic Mental Depression Mental disorders Meta-Analysis Methods Michigan Molecular Moods Nucleotides Participant Pathway interactions Persons Pharmacotherapy Phenotype Prevalence Prevention Prevention strategy Process Psychiatry Public Health Quality Control Research Research Personnel Resources Risk Schizophrenia Testing Universities Untranslated RNA Validation Variant analytical tool base case control cohort data sharing database of Genotypes and Phenotypes disorder risk experience follow-up genetic resource genetic variant genome analysis genome annotation genome sequencing genome wide association study genome-wide human disease improved innovation insertion/deletion mutation insight lifetime risk new technology novel research study risk variant tool trait

项目摘要

DESCRIPTION (provided by applicant): The goal of this collaborative project among investigators led by Drs. Michael Boehnke at the University of Michigan, Steven McCarroll of Harvard University and the Broad Institute, and Carlos Pato at the University of Southern California, is to use high-throughput DNA sequencing to identify genes and pathways that contribute to the risk for schizophrenia and bipolar disorder, and to construct a data resource for future genetic studies of these and other psychiatric disorders. This proposal builds on active collaborations among our groups on these important disorders and more generally on our experience in building genome variation resources, such as the 1000 Genomes Project, that are used throughout human genetics. Our research team combines strengths in high-throughput genetics and genomics, development and application of innovative computational and statistical analyses that maximize the benefits of new technologies, and leadership of large scientific consortia. In four Specific Aims, we propose whole genome sequencing (at ~30x coverage) and statistical analysis of 10,000 well-phenotyped and re-contactable individuals from the Genomic Psychiatry Cohort (GPC), equally divided among schizophrenia cases, bipolar cases, and psychiatrically normal controls, and comprised of equal numbers of European-Ancestry (EA), African-Ancestry (AA), and Latino individuals. We will carry out association analysis comparing schizophrenia cases to controls, bipolar cases to controls, and the combined cases to controls in the resulting sequence data, and by collaboration and meta-analysis with other investigators with relevant sequence data that become available. We will also use these sequence data as part of a reference panel to impute into tens of thousands of other genomes in the broader Psychiatric GWAS Consortium (PGC) data to allow association analysis based on substantially larger numbers of individuals. Finally, we will share data and methods to support similar studies of other psychiatric phenotypes and more broadly across the scientific community. The successful completion of these aims will provide new insights into molecular etiology that could catalyze breakthroughs in the prevention, treatment, and diagnosis of schizophrenia and bipolar disorder.